State-of-the-art in the management of locally advanced and metastatic gallbladder cancer

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 425-431

  McNamara, Mairéad G ^a   Metran Nascente, Cristiane ^a   Knox, Jennifer J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

biliary tract cancer; chemotherapy; gallbladder cancer; prognostic markers; targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; MUCIN 4; NECTIN 2; OXALIPLATIN; PACLITAXEL; PEROXIREDOXIN 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SELUMETINIB; SORAFENIB; TRASTUZUMAB; VASCULOTROPIN;

ANEMIA; ANTIPROLIFERATIVE ACTIVITY; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; CANCER CONTROL; CANCER STAGING; CELL CYCLE S PHASE; CHOLESTASIS; CHRONIC CHOLECYSTITIS; DNA SYNTHESIS; ENZYME ACTIVE SITE; EXTERNAL BEAM RADIOTHERAPY; GALLBLADDER CARCINOMA; GENE FREQUENCY; GENOTYPE; HEALTH CARE QUALITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LYMPH NODE METASTASIS; MALIGNANT ASCITES; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NATIONAL HEALTH ORGANIZATION; NEUTROPHILIA; OBSTRUCTIVE JAUNDICE; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; THROMBOCYTOSIS; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UNITED KINGDOM;

ANIMALS; ANTINEOPLASTIC AGENTS; GALLBLADDER NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS;

EID: 84879885959     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283620fd8     Document Type: Review

References (52)

1. Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012; 27:642-653.
2. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology 2009; 55:218-229.
3. deGroen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999; 341:1368-1378.
4. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273-1281.
5. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61:1657-1669.
6. Pfitzer J. Poiseuille and his law. Anaesthesia 1976; 31:273-275.
7. Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66:772-779. (Pubitemid 44436705)
8. Sasson AR, Hoffman JP, Ross E, et al. Trimodality therapy for advanced gallbladder cancer. Am Surg 2001; 67:277-283. (Pubitemid 33738872)
9. Uno T, Itami J, Aruga M, et al. Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor. Strahlenther Onkol 1996; 172:496-500. (Pubitemid 26293540)
10. Bonet Beltran M, Roth AD, Mentha G, Allal AS. Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer 2011; 11:267.
11. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007; 96:8-13. (Pubitemid 47015442)
12. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896-902. (Pubitemid 46452283)
13. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339-1343. (Pubitemid 39295020)
14. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332-2338. (Pubitemid 46218726)
15. Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as firstline treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98:309-315. (Pubitemid 351161262)
16. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gallbladder cancer: a randomized controlled study. J Clin Oncol 2010; 28:4581-4586.
17. Bridgewater J, Palmer D, Cunningham D, et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 2013; 49:1511.
18. Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of secondline chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013; 49:329-335.
19. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069-3074. (Pubitemid 46638942)
20. Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10:631.
21. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52:706-712. (Pubitemid 36528874)
22. Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11:1142-1148.
23. Malka D, Fartoux V, Trarbach T, et al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO). J Clin Oncol 2012; 30: Abstr 4032.
24. Hida Y, Morita T, Fujita M, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 1999; 19:2257-2260. (Pubitemid 29392531)
25. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11:48-54.
26. El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2012; 30:1646-1651.
27. Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206:356-365. (Pubitemid 40903200)
28. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98:418-425. (Pubitemid 351161240)
29. Treekitkarnmongkol W, Suthiphongchai T. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol 2010; 16:4047-4054.
30. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007; 13:4495-4502. (Pubitemid 47219719)
31. Ramanathan RK, Belani CP, Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC): A California Consortium (CCC-P) Trial. J Clin Oncol 2006; 24: abstr 4010.
32. Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol 2012; 30:e271-e273.
33. Horiuchi H, Kawamata H, Furihata T, et al. A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice. J Exp Clin Cancer Res 2004; 23:599-606.
34. Horiuchi H, Kawamata H, Fujimori T, Kuroda Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003; 23:957-963.
35. Bekaii-Saab T, Phelps MA, Li X, et al. Multiinstitutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29:2357-2363.
36. Xu J, Knox JJ, Ibrahimov E, et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res 2013; 19:118-127.
37. Deshpande V, Nduaguba A, Zimmerman SM, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011; 11:60.
38. Wasan HS, Valle JW, Palmer DH, et al. Predictors of survival in patients with advanced biliary tract cancer: Results from the UK ABC-02 randomized phase III trial. J Clin Oncol 2010; abstr 199.
39. Du X, Zhao H, Zang L, et al. Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma. Pathol Oncol Res 2012 [Epub ahead of print].
40. Zhai G, Yan K, Ji X, et al. LAPTM4B allele-2 is a marker of poor prognosis for gallbladder carcinoma. PLoS One 2012; 7:e45290.
41. Miao X, Yang ZL, Xiong L, et al. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. J Clin Exp Pathol 2013; 6:179-190.
42. Li J, Yang ZL, Ren X, et al. ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol 2012; 34:359-368.
43. Kim SM, Oh SJ, Hur B. Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. Korean J Pathol 2012; 46:429-435.
44. Lee HK, Cho MS, Kim TH. Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Oncol 2012; 10:224.
45. Liu DC, Yang ZL. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011; 207:472-478.
46. Chang HJ, Yoo BC, Kim SW, et al. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 2007; 13:326-335. (Pubitemid 351287314)
47. Li QL, Yang ZL, Liu JQ, et al. Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome. Pathol Oncol Res 2011; 17:561-568.
48. Karamitopoulou E, Tornillo L, Zlobed I, et al. Clinical significance of cell cycleand apoptosis-related markers in biliary tract cancer: a tissue microarraybased approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 2008; 130:780-786.
49. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16:1597-1604.
50. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17:72-79.
51. Gupta P, Agarwal A, Gupta V, et al. Expression and clinicopathological significance of estrogen and progesterone receptors in gallbladder cancer. Gastrointest Cancer Res 2012; 5:41-47.
52. Tan Z, Li M, Wu W, et al. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol Cell Biochem 2012; 369:27-33.